AbbVie Inc (ABBV)vsMeridian Bioscience Inc (VIVO)
ABBV
AbbVie Inc
$205.07
-0.56%
HEALTHCARE · Cap: $391.56B
VIVO
Meridian Bioscience Inc
$2.24
-5.49%
HEALTHCARE · Cap: $1.49B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 18265% more annual revenue ($61.16B vs $333.02M). VIVO leads profitability with a 12.8% profit margin vs 6.9%. ABBV appears more attractively valued with a PEG of 0.53. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
VIVO
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1179.3%
Fair Value
$16.12
Current Price
$205.07
$188.95 premium
Margin of Safety
N/A
Fair Value
$6.53
Current Price
$2.24
$4.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 22.7%
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Revenue declined 13.8%
Earnings declined 13.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bull Case : VIVO
The strongest argument for VIVO centers on Price/Book, Operating Margin. PEG of 1.33 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 93.4x leaves little room for execution misses.
Bear Case : VIVO
The primary concerns for VIVO are P/E Ratio, Market Cap, Revenue Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while VIVO is a declining play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.33 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Meridian Bioscience Inc
HEALTHCARE · PHARMACEUTICALS · USA
Meridian Bioscience, Inc., a life sciences company, develops, manufactures, distributes and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases and elevated blood lead levels worldwide. The company is headquartered in Cincinnati, Ohio.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?